Abstract：
UNASSIGNED: The current outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread throughout the world. During treatment, we found that the majority of patients had a decrease in hemoglobin (Hb). Interferon-α2b (IFN-α2b) was the primary suspected drug that was related to Hb reduction. Thus, the study aimed to investigate whether IFN-α2b could induce Hb reduction in severe patients with COVID-19 and its potential mechanism.
UNASSIGNED: A total of 50 patients who were admitted to the First Affiliated Hospital of Harbin Medical University with severe COVID-19 infection were enrolled from February 12th to 24th, 2020. The demographics, baseline characteristics, clinical data, and therapeutic regimen were collected retrospectively. The patients were divided into two groups according to the declined use of IFN-α2b on day 14. The Hb levels on admission, day 7, day14, and day 21 were collected and analyzed. The primary endpoint was the level of Hb on day 21.
UNASSIGNED: A total of 31 patients in the IFN-stop group and 19 patients in the non-IFN-stop group were reviewed. The age, gender, comorbidities, clinical symptoms, nutritional status, disease severity, complications, and other factors of the patients were compared, no difference was found between the IFN-stop group and the non-IFN-stop group. The Hb levels of all patients significantly decreased on day 7 compared with that on admission (p < .0001). In the IFN-stop group, the Hb level was increased in 7 days after IFN-α2b was stopped (p = .0008), whereas no difference was found between day 14 and day 21 in the non-IFN-stop group (p = .3152).
UNASSIGNED: IFN-α2b was associated with Hb reduction in the treatment of severe patients of COVID-19. Clinicians should be aware of the high incidence of Hb reduction for patients treated by IFN-α2b.
UNASSIGNED: A total of 50 patients who were admitted to the First Affiliated Hospital of Harbin Medical University with severe COVID-19 infection were enrolled from February 12th to 24th, 2020. The demographics, baseline characteristics, clinical data, and therapeutic regimen were collected retrospectively. The patients were divided into two groups according to the declined use of IFN-α2b on day 14. The Hb levels on admission, day 7, day14, and day 21 were collected and analyzed. The primary endpoint was the level of Hb on day 21.
UNASSIGNED: A total of 31 patients in the IFN-stop group and 19 patients in the non-IFN-stop group were reviewed. The age, gender, comorbidities, clinical symptoms, nutritional status, disease severity, complications, and other factors of the patients were compared, no difference was found between the IFN-stop group and the non-IFN-stop group. The Hb levels of all patients significantly decreased on day 7 compared with that on admission (p < .0001). In the IFN-stop group, the Hb level was increased in 7 days after IFN-α2b was stopped (p = .0008), whereas no difference was found between day 14 and day 21 in the non-IFN-stop group (p = .3152).
UNASSIGNED: IFN-α2b was associated with Hb reduction in the treatment of severe patients of COVID-19. Clinicians should be aware of the high incidence of Hb reduction for patients treated by IFN-α2b.
摘要：
■当前2019年冠状病毒病（COVID-19）的爆发已在全球迅速蔓延。治疗期间,我们发现大多数患者的血红蛋白(Hb)下降.干扰素-α2b（IFN-α2b）是与Hb降低有关的主要可疑药物。因此，本研究旨在探讨IFN-α2b是否能诱导COVID-19重症患者Hb降低及其可能的机制。
2月12日至24日，哈尔滨医科大学附属第一医院收治的50例COVID-19重症感染患者，2020年。人口统计，基线特征，临床资料,回顾性收集治疗方案。根据第14天IFN-α2b的使用减少，将患者分为两组。入院时的Hb水平，收集并分析第7天,第14天和第21天.主要终点是第21天的Hb水平。
■对IFN-停止组31例患者和非IFN-停止组19例患者进行了回顾。年龄,性别,合并症,临床症状,营养状况,疾病严重程度,并发症,和患者的其他因素进行比较，IFN停止组和非IFN停止组之间无差异.与入院时相比，所有患者的Hb水平在第7天显着降低（p<0.0001）。在IFN停止组中，Hb水平在IFN-α2b停止后7天增加（p=.0008），而在非IFN停止组的第14天和第21天之间没有发现差异（p=.3152）。
■在COVID-19重症患者的治疗中，IFN-α2b与Hb降低相关。临床医生应该意识到IFN-α2b治疗的患者Hb降低的高发生率。
2月12日至24日，哈尔滨医科大学附属第一医院收治的50例COVID-19重症感染患者，2020年。人口统计，基线特征，临床资料,回顾性收集治疗方案。根据第14天IFN-α2b的使用减少，将患者分为两组。入院时的Hb水平，收集并分析第7天,第14天和第21天.主要终点是第21天的Hb水平。
■对IFN-停止组31例患者和非IFN-停止组19例患者进行了回顾。年龄,性别,合并症,临床症状,营养状况,疾病严重程度,并发症,和患者的其他因素进行比较，IFN停止组和非IFN停止组之间无差异.与入院时相比，所有患者的Hb水平在第7天显着降低（p<0.0001）。在IFN停止组中，Hb水平在IFN-α2b停止后7天增加（p=.0008），而在非IFN停止组的第14天和第21天之间没有发现差异（p=.3152）。
■在COVID-19重症患者的治疗中，IFN-α2b与Hb降低相关。临床医生应该意识到IFN-α2b治疗的患者Hb降低的高发生率。
